Publications
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Atezolizumab in the first-line treatment of non-small cell lung cancer - the IMpower110 trial2022 | First Faculty of Medicine
- Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment2021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Treatment of ALK positive non-small cell lung cancer2021 | First Faculty of Medicine
- Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer2020 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- What approach to ALK-positive NSCLC?2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Lorlatinib in the treatment of non-small cell lung cancer2020 | First Faculty of Medicine
Loading network view...